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Abstract: A target-speciﬁ  c MRI contrast agent for tumor cells expressing high afﬁ  nity folate 
receptor was synthesized using generation ﬁ  ve (G5) of polyamidoamine (PAMAM) dendrimer. 
Surface modiﬁ  ed dendrimer was functionalized for targeting with folic acid (FA) and the remain-
ing terminal primary amines of the dendrimer were conjugated with the bifunctional NCS-DOTA 
chelator that forms stable complexes with gadolinium (Gd III). Dendrimer-DOTA conjugates 
were then complexed with GdCl3, followed by ICP-OES as well as MRI measurement of their 
longitudinal relaxivity (T1 s−1 mM−1) of water. In xenograft tumors established in immunode-
ﬁ  cient (SCID) mice with KB human epithelial cancer cells expressing folate receptor (FAR), 
the 3D MRI results showed speciﬁ  c and statistically signiﬁ  cant signal enhancement in tumors 
generated with targeted Gd(III)-DOTA-G5-FA compared with signal generated by non-targeted 
Gd(III)-DOTA-G5 contrast nanoparticle. The targeted dendrimer contrast nanoparticles inﬁ  l-
trated tumor and were retained in tumor cells up to 48 hours post-injection of targeted contrast 
nanoparticle. The presence of folic acid on the dendrimer resulted in speciﬁ  c delivery of the 
nanoparticle to tissues and xenograft tumor cells expressing folate receptor in vivo. We present 
the speciﬁ  city of the dendrimer nanoparticles for targeted cancer imaging with the prolonged 
clearance time compared with the current clinically approved gadodiamide (OmniscanTM) contrast 
agent. Potential application of this approach may include determination of the folate receptor 
status of tumors and monitoring of drug therapy.
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Introduction
Clinical applications of magnetic resonance imaging (MRI) require generation of tis-
sue-speciﬁ  c contrast. Numerous pulse sequences and methods have been designed to 
exploit signal differences created by endogenous contrast mechanisms such as T1, T2, 
the BOLD effect (Logothetis and Pfeuffer 2004), magnetization transfer (van Buchem 
and Tofts 2000), ﬂ  ow, and diffusion (Bammer et al 2005). Other imaging methods rely on 
injection or inhalation of contrast agents such as gadolinium (Gd) chelates or hyperpolar-
ized gases (Swanson et al 1997, 1999). Chelates of gadolinium ion such as Gd-DTPA 
generate contrast by increasing the relaxation rate of nearby water protons and are used 
in nearly half of all diagnostic MRI procedures (Shellock and Kanal 1999; Bellin 2006). 
These contrast agents are effective in diagnosis and staging of brain tumors by measuring 
the breakdown of the blood-brain barrier and in breast cancer by measuring enhanced 
uptake in breast tumors (Leach et al 2003). The contrast is generated by morphological 
changes to the tissue and not by targeting speciﬁ  c molecular aspects of the tumors. Indeed, 
speciﬁ  c targeting of cancer cells for imaging and treatment is thought to be a key compo-
nent of cancer management in the near future and is currently an active area of research. 
Though a variety of molecular agents will likely play a role, the physical, chemical, International Journal of Nanomedicine 2008:3(2) 202
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and biological characteristics of branched polyamidoamide 
(PAMAM) dendrimers make this class of molecules an ideal 
platform for targeted therapeutic and contrast agents (Wiener 
et al 1994; Konda et al 2001; Konda et al 2002; Patri et al 2002; 
Kukowska-Latallo et al 2005; Venditto et al 2005).
PAMAM dendrimers are synthetic biocompatible mac-
romolecules possessing multiple free amino groups on the 
surface. Generation-5 (G5) PAMAM dendrimers offer a carrier 
system having a deﬁ  ned branched structure capable of carry-
ing multiple molecular entities, with a highly uniform size of 
about 5 nm in diameter (Kobayashi and Brechbiel 2005). The 
surface amino groups can be used for conjugation to molecules 
such as a dye or a drug to target cells in vitro and in vivo 
(Quintana et al 2002; Kukowska-Latallo et al 2005; Thomas 
et al 2005). PAMAM dendrimers are among the most promis-
ing of nanoparticle systems suggested recently because of their 
proven solubility in aqueous solutions, accessibility through the 
vasculature, lack of immunogenicity, and excretion through 
the kidney (Kukowska-Latallo et al 2005). The dendrimer 
platform allows synthesis of a nanometer size contrast particles 
(Kobayashi and Brechbiel 2005; Nasongkla et al 2006).
Targeting of the high afﬁ  nity folate receptor for drug and 
contrast agent delivery provides one pathway for selective 
enhancement and/or treatment (Hilgenbrink and Low 2005). 
Initial studies by Konda et al using G4 dendrimers coupled 
with both folic acid (FA) and chelate (DTPA), and then 
complexed with gadolinium showed a promising targeted 
enhancement in ovarian tumor xenografts (Konda et al 2001). 
Therapeutic uses previously reported by us employed G5 
PAMAM dendrimer conjugated with folic acid and metho-
trexate that speciﬁ  cally killed FA receptor-expressing human 
epithelial cancer cells (KB) by intracellular delivery of the 
drug through receptor-mediated endocytosis in vitro and in 
vivo (Kukowska-Latallo et al 2005; Patri et al 2005).
In this study, we present the pharmacokinetics and tissue 
distribution of G5 PAMAM dendrimer conjugated with folic 
acid and DOTA-NCS, and complexed with gadolinium (Gd 
III) in a murine model of human cancer. To control for non-
speciﬁ  c uptake of dendrimer, both targeted and non-targeted 
contrast agents were synthesized and studied. We report 
speciﬁ  c binding of the folic acid targeted contrast agents to 
folate receptor expressing tumor cells in vivo.
Materials and methods
Synthesis of dendrimer-gadolinium 
nanoparticle
The PAMAM generation 5 (G5) dendrimers were synthesized 
at the Michigan Nanotechnology Institute for Medicine 
and Biological Sciences. Folic acid (FA), acetic anhydride, 
triethylamine, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and all the solvents were 
purchased from Sigma-Aldrich (USA). The bifunctional 
chelating agent DOTA-NCS (1,4,7,10-tetraazacyclodo-
decane-1,4,7,10-tetraacetic acid, α-[5-isothiocyanato-2-
methoxyphenyl]-, hydrochloride [9Cl]) was provided by Dow 
Chemical Company (Midland, MI, USA).
Two contrast nanoparticles were synthesized and 
evaluated; targeted Gd(III)-DOTA-G5-FA contrast agent 
and a non-targeted Gd(III)-DOTA-G5. The G5 PAMAM   
dendrimer was ﬁ  rst recovered from concentrated G5/
methanol solution by the removal of methanol and 
lyophilization in water. For targeting experiments G5 
dendrimer was conjugated with an average of 4.5 folic acid 
molecules conjugated to free amines. In partial acetylation 
that was carried out to improve the solubility of the ﬁ  nal 
dendrimer-Gd complex 50 of 110 primary amine groups 
of the dendrimer were acetylated as shown in schematic 
synthesis of dendritic contrast agents (Scheme 1). The 
remaining terminal primary amines of the dendrimer were 
conjugated with the bifunctional DOTA-NCS. The control 
G5 PAMAM dendrimer was completely surface function-
alized with DOTA-NCS chelator without targeting folic 
acid moiety on the surface. The isothiocyanate reaction 
was run at pH 9 to generate free amines at a molar ratio 
of DOTA to amine equal 2:1. The dendritic chelator was 
then complexed with 30% molar excess of GdCl3.6H2O 
at pH 6 adjusted with citrate buffer. The reaction was 
performed at room temperature and was completed in 48 
hours. The conjugates were puriﬁ  ed in amicon stirred cell 
with 10 K MWCO membrane. The dendrimers conjugated 
with chelators (without Gd) were characterized by NMR, 
HPLC and GPC. Dendritic chelators were titrated with 
GdCl3 and followed by ICP-OES spectroscopy as well 
as their longitudinal relaxation times (T1) of water. The 
absence of free Gd(III) was conﬁ  rmed by comparing UV-
Vis spectra of G5 dendrimer conjugate complexed with 
Gd before and after addition of photometric Arsenazo III 
agent (Nagaraja et al 2006). The Gd(III) concentration of 
the contrast agents was quantiﬁ  ed by inductive coupled 
plasma-optical emission spectrometry (ICP-OES). Analysis 
revealed that targeted imaging agent [Gd(III)-DOTA-G5-
FA] was loaded with 6.0% of Gd(III) and the non-targeted 
contrast agent [Gd(III)-DOTA-G5] was loaded with 7.7% 
of Gd. Both compounds were dissolved in sterile saline 
to equimolar concentrations of Gd(III) at 0.45 mg/mL 
and 0.9 mg/mL.International Journal of Nanomedicine 2008:3(2) 203
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MR imaging in vitro
The KB human cell line over-expresses folate receptor (FAR) 
when grown in folate-deﬁ  cient medium (Kukowska-Latallo 
et al 2005). Cells were purchased from the American Type 
Culture Collection (ATCC, Manassas, VA, USA) and main-
tained at 37 °C with 5% CO2 in folate-deﬁ  cient RPMI 1640 
supplemented with penicillin (100 units/mL), streptomycin 
(100 µg/mL), and 10% heat-inactivated FBS. Cell suspensions 
created with 5 × 106 KB cells in PBS (phosphate-buffered 
saline) were incubated with targeted and non-targeted contrast 
agents at 0.01 mM concentration of Gd(III) at 4 °C for 30 min. 
Following incubation cells were washed 3 times with PBS 
and centrifuged each time at 500 × g for 5 min. After removal 
of supernatant the volume of cell pellets was approximately 
100 µL. The relaxation rates of labeled cells in wet pellets 
were measured at 2T and at 20 °C.
Recipient animal and tumor model
A murine tumor model was established in NOD C.B-17 
SCID mice using human KB tumor cells over-expressing 
folate receptor as described previously (Kukowska-Latallo 
et al 2005). Briefly, 5- to 6-week-old FOX CHASE 
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Scheme 1 The synthesis of control (Gd[III]-DOTA-G5) and FA targeted dendritic chelate (Gd[III]-DOTA-G5-FA). After conjugation of 4.5 (on average) of folic acid molecules 
to G5 PAMAM dendrimer (a), 50 of the primary amine groups were acetylated (b), the remaining primary amines conjugated with bifunctional NCS-DOTA (c) and complexed 
with GdCl3.6H2O (d). The structure of the DOTA-NCS used for conjugation of contrast agents (lower panel).International Journal of Nanomedicine 2008:3(2) 204
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SCID (C.B-17/lcrCrl-scidBR) female mice were purchased 
from the Charles River Laboratories (Wilmington, MA, USA) 
and housed in a speciﬁ  c pathogen-free animal facility at the 
University of Michigan Health System in accordance with 
the regulations of the University’s Committee on the Use and 
Care of Animals (UCUCA) as well as with federal guidelines, 
including the Principles of Laboratory Animal Care. Animals 
were fed ad libitum with Laboratory Autoclavable Rodent 
Diet 5010 (PMI Nutrition International, St. Louis, MO, 
USA). The food was changed to a folate-deficient diet 
(TestDiet, Richmond, IN, USA) for 7 days prior to injection 
of tumor KB cells on both ﬂ  anks of mice. Normal rodent 
chow contains a high concentration of folic acid (6 mg/kg 
chow) and on this diet the mouse serum folate concentration 
is about 50 times higher than human. Using the low folate diet 
brings down mouse serum levels to about 2 times the folate 
concentration in normal human serum (Mathias et al 1998). 
The FR receptor in the tumor is not altered due to this dietary 
intervention (Kukowska-Latallo et al 2005). Subcutaneous 
KB tumor nodules appeared 7–10 days post-implantation. 
Anesthesia for imaging was induced by placing mice in a 
chamber with 2.0% isoﬂ  uroane (SBH Scientiﬁ  c). Following 
anesthetic induction, the mice were transferred to the MRI 
probe and anesthesia was maintained at 1.25% isoﬂ  urane 
for the duration of the study. All procedures were performed 
under protocol approval by UCUCA at the University of 
Michigan.
Delivery of Gd(III) contrast nanoparticle
Imaging agent was delivered through intravenous injection 
at 20 or 30 days post-implantation. The Gd(III)-DOTA-
G5-FA and the non-targeted Gd(III)-DOTA-G5 dendrimer 
nanoparticles were delivered via the tail vein in 0.2 mL 
of saline at 0.029 mmol of Gd/kg and at 0.071 mmol/kg. 
Two-dimensional and three-dimensional MRI images were 
obtained both before and after administration of either 
imaging agent at 1, 4, 24, 48, and 96 hours post injection.
MR imaging in vivo
The MRI probe, constructed speciﬁ  cally for these studies, was 
based on an Alderman-Grant slotted cylinder design (length 10 
cm, OD 4.5 cm). The probe was made with polycarbonate tub-
ing, copper tape, and ATC and Johanson capacitors. Following 
induced anesthesia, the mouse to be imaged was placed inside 
a second polycarbonate tube (ID 2.6 cm). This second tube 
was then inserted into the MR probe, allowing easy animal 
positioning and restricting mouse MR studies to a region of 
homogeneous RF ﬁ  eld. MRI was performed on a 2T Varian 
Unity/Inova system equipped with Acustar S180 gradients.
The 2D and 3D gradient-echo MR images were obtained 
at each time point for each animal. Two sets of interleaved, 
2D gradient-echo images were acquired with 2 mm slice 
thickness, TR/TE 100/5 ms, ﬂ  ip angle 45°, in plane resolution 
390 µm, and 8 averages. Total time to acquire the 2D images 
was 2.5 minutes. The 3D gradient-echo images were acquired 
with a TR/TE of 20/4 ms, a ﬂ  ip angle of 20°, isotropic voxel 
resolution of 390 µm, and 4 averages. Imaging time for the 
3D dataset was 5.5 min. The 3D gradient echo pulse sequence 
was chosen to provide isotropic spatial resolution, minimize 
motion artifacts, and generate T1 weighted MR images.
All image data were transferred to a remote computer 
(Dual 2 GHz PowerPC G5 Macintosh) for data process-
ing. Matlab (The Mathworks, Natick, MA, USA) was used 
to convert the k-space MR data sets into quantitative MR 
images and to combine all images of the study into a single 
dataset. Tumor was typically present in 30 of 64 planes in 
the 3D image. The entire tumor was selected from the dataset 
and used to generate normalized histograms of the signal 
intensity. Using the data from 3D MR studies assures that the 
entire tissue of interest is examined and is not biased toward 
anomalously enhancing regions. The percentage enhancement 
was calculated for each of the images acquired at each time 
following injection of either the targeted or the non-targeted 
contrast agent. The normalized histogram of the percentage 
signal enhancement was created by deﬁ  ning the sum of all 
signals to 100%. Histograms in the ﬁ  gures are plotted as the 
percentage of voxels at a given percentage enhancement.
Statistical methods
To test the hypothesis that targeted contrast agent generates 
statistically signiﬁ  cant signal enhancement, a 2-sample Kol-
mogorov-Smirnov (Massey 1951) (KS) test was used (Matlab, 
Natick, MA, USA). The KS test was applied to the normal-
ized histograms of the signal intensities of the MR data from 
targeted and non-targeted contrast agent studies in tumor and 
other tissues. This statistic was chosen because the distribution 
of signal intensity generated by the contrast agent is not neces-
sarily normal and because the large number of voxel intensities 
generates a well sampled distribution. P-values of less that 0.05 
allow us to reject the null hypothesis that the two samples are 
drawn from the same underlying population.
Results
The relaxivity of the contrast agents measured in solutions 
at 2T and at 20°C was 26.0 ± 0.1 s−1 mM−1 for targeted International Journal of Nanomedicine 2008:3(2) 205
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Table 1 Relaxation rates (R1) ± estimated error of inversion 
recovery ﬁ  t of KB cells labeled with non-targeted and targeted (FA) 
Gd loaded G5 dendrimers, both at adjusted 0.01 mM concentration 
of Gd, were measured in wet cell pellets. Increased relaxation rate 
of cells labeled with the targeted contrast agent indicates speciﬁ  c 
binding to KB cells. Cell pellets were created with 5 × 106 cells and 
had an approximate volume of 100 µL. All relaxation rates were 
measured at 2T and at 20°C
Compound R1  (s−1)
Gd(III)-DOTA-G5 0.479  ± 0.013
Gd(III)-DOTA-G5-FA 0.877  ± 0.001
none 0.484  ± 0.001
Gd(III)-DOTA-G5-FA agent and 19.4 ± 0.04 s−1 mM−1 for 
the non-targeted Gd(III)-DOTA-G5 agent. The calculated 
relaxivity of the milimole of the targeted and non-targeted 
contrast nanoparticle is 598 s−1 mM−1 and 532 s−1 mM−1, 
respectively. In comparison gadolinium complex of diethyl-
enetriamine pentaacetic acid bismethylamide used as clinical 
contrast (Gd(III)-DTPA-BMA; Omniscan™), has a relaxiv-
ity of 3.9 s−1 mM−1 in solution (Bellin 2006). The relaxivity 
of Gd chelates bonded to these dendrimers is more than 4 
times greater than Omniscan™. The increased relaxivity is 
due to a decrease of the rotational correlation time of the Gd-
dendrimer complex (Bryant et al 1999; Nicolle et al 2002; 
Laus et al 2005; Rudovsky et al 2006). For contrast agents 
such as these molecules, increased relaxivity is one of the 
most important measures of the effectiveness of the contrast 
agent. Therefore, the increased relaxivity is a very desirable 
property of dendrimer contrast agents.
Targeting speciﬁ  city was measured in vitro by incubating 
KB tumor cells over-expressing folate receptor to targeted 
and non-targeted contrast agents at 0.01 mM concentration 
of Gd(III). Relaxation rate R1 of wet cell pellets after incuba-
tion of cells with each contrast agent was measured in 2.0 T 
MR system and at 20 °C, and was compared with untreated 
cells. The targeted contrast agent speciﬁ  cally binds to KB 
tumor cells and increases the water proton relaxation rate 
whereas the non-targeted contrast agent creates no additional 
relaxation when compared to the relaxation rate of untreated 
cells (Table 1).
The in vivo MRI results using dendrimer nanopar-
ticles are presented on one slice of the 3D dataset from 
the images acquired following injection of either targeted 
Gd(III)-DOTA-G5-FA or non-targeted Gd(III)-DOTA-G5 
(Figure 1). The image has been colorized to allow easy 
visualization of the contrast changes as a function of time 
post-injection. The control image was obtained from mouse 
injected with saline (Figure 1a). The animals injected with 
FAR-targeted contrast agent presented increased signal 
intensity in liver, kidney, gut, and tumor (Figure 1a). Data 
from tumor were selected and used to create the normal-
ized histograms of signal enhancement for all time points 
post-injection (Figure 1b and 1c). Due to the presence of 
the high-molecular weight contrast agent there is already 
signiﬁ  cant signal enhancement at 1 hour (red line) that 
remains at the same level at 4 hours (green line) with slow 
decrease starting at 24 hours (blue line) and continuing at 
48 hours (black) (Figure 1b). These data show increase 
in both the average signal enhancement and the spread of 
the signal enhancement. The non-speciﬁ  c enhancement of 
non-targeted Gd(III)-DOTA-G5 contrast is present only 
at 1 hour (red line), prior to being cleared by the kidney 
(Figure 1c). This clearance is supported by very bright 
signal intensity of water in the bladder obtained for the 1 
hour and 4 hour images (data not shown). Statistical analysis 
(KS test) performed between the time matched histograms 
of the targeted tumor (Figure 1b) and histograms of non-
targeted tumor (Figure 1c) showed statistically signiﬁ  cant 
differences at 1, 4, and 24 hours (Table 2).
Data selected from liver, kidney and muscle tissue were 
reduced to normalized histogram of signal enhancements 
as described above. The averages ±SD of the percent signal 
enhancement is shown for tumor, kidney, liver, and muscle, 
for both targeted and non-targeted contrast agent and for all 
times post-injection (Figure 2a, b, c, d). In addition to the 
tumor enhancement, signiﬁ  cant signal enhancement for the 
targeted contrast agent study is observed for kidney and liver 
tissues at 1 and 4 hours post injection (Figure 2b, c). Enhance-
ment in kidney and liver is expected due to expression of folic 
acid receptors in these tissues (Figure 2b and 2c) (Parker 
et al 2005). Muscle, with no known expression of folate 
receptor, does not show signiﬁ  cant enhancement for either 
the targeted or the non-targeted contrast agent (Figure 2d) 
(Parker et al 2005).
An additional study of the differential enhancement of 
tumors with targeted and non-targeted Gd(III)-DOTA-G5 
was performed using higher dose of contrast (0.072 mmol/kg),
comparable and recommended for clinical gadolinium 
contrast agent, Omniscan™ (Figure 3a, b, c, d). Targeted 
compound generates further increased signal enhancement 
when compared to the results of Gd(III)-DOTA-G5-FA in 
Figure 1. The most signiﬁ  cant difference was observed at 
4 hour post-injection showing no overlap between histo-
grams for targeted and non-targeted contrast nanoparticles 
(Figure 3a, b). The signal is maintained for up to 48 hours 
(Figure 3c) compared with 24 hours in the earlier study International Journal of Nanomedicine 2008:3(2) 206
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Figure 1 MR imaged uptake of targeted and non-targeted contrast nanoparticles delivered at 0.029 mmol/kg of Gd. The top image is of a control mouse injected with saline 
and imaged at 1hour (a). The series of images on the left from the mouse injected with targeted contrast Gd(III)-DOTA-G5-FA and on the right from the mouse injected with 
the non-targeted contrast agent Gd(III)-DOTA-G5 were collected at 1, 4, 24, and 48 hours post-injection (a). The circles are drawn around the tumor to guide the eye. Signal 
enhancement is created by increased water proton relaxation due to the presence of the contrast agent. Normalized histograms of the voxel intensities were created for the 
whole tumors on both ﬂ  anks of mouse, for the two mice injected with targeted and non-targeted contrast presented on the series of images (a). Comparison of targeted 
(b) and non-targeted contrast (c) showed statistically signiﬁ  cant difference (Table 2; KS test, p  0.05) between the signals collected at 1, 4, and 24 hours.International Journal of Nanomedicine 2008:3(2) 207
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(Figure 1c). The increased signal intensities due to higher 
concentration of contrast give more efﬁ  cient in vivo relax-
ation and stronger saturation of the folate receptor. The differ-
ence in the spreads of the distributions between non-targeted 
contrast agents (Figure 3c and 3d) can be further explained 
by the fact that the ﬁ  rst study was begun 20 days following 
tumor implantation (Figure 1) and the second one was started 
30 days after implantation (Figure 3). The larger size of tumors 
could account for a broader signal intensity distribution.
To control for non-speciﬁ  c uptake for targeted-dendrimer 
nanoparticle an additional study was performed using a mouse 
with different xenograft tumors on each ﬂ  ank, one side with 
KB cells expressing FAR and the other with MCA207 cells 
negative for FAR (Figure 4). The signal enhancement was 
observed in KB tumors positive for FAR when folate-targeted 
dendrimer contrast was delivered (Figure 4, right panel, A). 
Some capture was observed for MCA207 tumor, but largely 
to the same extent as of non-targeted dendrimer contrast in 
both MCA207 and KB tumors (Figure 4, right panel, B).
Table 2 P values of KS test between normalized histograms of signal 
intensities of the MR data from Gd(III)-DOTA-G5-FA and Gd(III)-
DOTA-G5 contrast agents in tumors shown in Figure 1b and 1c. His-
tograms at 1, 4, and 24 hours show a statistically signiﬁ  cant difference. 
P values of less than 0.05 allow us to reject the null hypothesis that 
the two samples are drawn from the same underlying population
Time (hours)  P value KS test
1  = 0.00001
4  = 0.00096
24  = 0.00017
48  = 0.50 (ns)
e
s
e
s
e
s
e
s
Figure 2 Signal enhancement in tumor (a), kidney (b), liver (c) and, muscle (d) in the two mice injected with targeted [Gd(III)-DOTA-G5-FA] or non-targeted [Gd(III)-DOTA-G5] 
contrast presented in Figure 1a.   A signiﬁ  cant difference between signal enhancement of the two contrast agents is observed at 1, 4, and 24 hours for the tumor (a) and at 1 and 
4 hours for the kidney (b) and the liver (c) indicating preferential uptake of targeted contrast agent. Signal in muscle shows no enhancement for either contrast agent (d).International Journal of Nanomedicine 2008:3(2) 208
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Figure 4 Surface rendering (left panel) and signal enhancement images (right panel) of the same pair of mice bearing KB tumors (upper ﬂ  ank of mouse) and MCA207 tumors 
(lower ﬂ  ank of mouse) injected with folate-targeted contrast nanoparticle (A) and non-targeted contrast nanoparticle (B). The KB tumor that expresses FAR showed signal 
enhancement at 24 hours post-injection of targeted-contrast (right panel, A, upper ﬂ  ank) compared with some capture in MCA207 tumor, which was non-speciﬁ  c for both 
targeted and non-targeted contrast nanoparticles.
e
e e
Figure 3 MR images obtained at a higher dose of Gd (0.072 mmol/kg) of targeted Gd(III)-DOTA-G5-FA and non-targeted Gd(III)-DOTA-G5 contrast nanoparticles (a). A 
signiﬁ  cant difference in the signal intensity is observed at 4 hours (b) and from 1 to 24 hours post-injection of contrast nanoparticles (c, d). The signal persists up to 48 hours 
post-injection (c) with a minimal overlap between targeted and non-targeted contrast agents up to 24 hours (c, d).International Journal of Nanomedicine 2008:3(2) 209
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Discussion
Improvement of the diagnostic speciﬁ  city of MRI imaging 
can be achieved through application of different types of 
imaging probes that provide high-resolution anatomical 
information and functional measurement of tumor physiol-
ogy (Nasongkla et al 2006; Talanov et al 2006). MRI contrast 
probes containing a paramagnetic cation or nanosized par-
ticle can be classiﬁ  ed as non-speciﬁ  c, targeted or activatable 
(Mathias et al 2003). Targeting of imaging agents is cur-
rently a vibrant area of active research. Speciﬁ  c localization 
to deﬁ  ned cells via internalization or interaction with cell 
surface proteins of target cell can result in tumor-speciﬁ  c 
accumulation and enhanced detection of tumor burden in vivo 
(Kobayashi et al 2004; Nasongkla et al 2006). The increased 
retention of targeted probes compared with rapidly diffusing 
Gd(III) chelates used for clinical MRI examinations allows 
for longer time of detection due to increased stability in vivo 
(Figures 1–3). Taken together, our results indicate that tar-
geted MR nanoparticles can be used to follow the adminis-
tration of different therapeutic agents, thereby contributing 
to the effectiveness of a drug. The technique may be used 
to screen cancers for receptor status and to follow up drug 
therapy in tumors responding to therapy. The targeted folate-
dendrimer nanoparticles were taken up heavily in the liver, 
bowel and kidney due to excretion of the conjugates and the 
presence of folate receptors in these tissues. The possible 
clinical targets for the imaging technique presented here 
could be ovarian, breast, and head and neck tumors (Kalli 
et al 2008). Dendrimer-based delivery of contrast has several 
additional advantages including small size (~30 kD) compa-
rable to size of proteins, that allows escape from vasculature 
and target tumor cells while also being below the threshold 
of renal ﬁ  ltration and therefore removing a requirement for 
hepatic metabolism. The G5 dendrimer is stable, provides 
stability for Gd chelates, is non-immunogenic, and contains 
ample reactive sites for the conjugation of complex drug 
delivery systems (Kukowska-Latallo et al 2005).
Our study uses the dendrimer-gadolinium nanoparticles 
as a T1 contrast agent. The experiments were performed 
with G5 dendrimer at 2.0 T. At 2.0 T, the high molecular 
weight slows the rotation of the G5 Gd-dendrimer complex 
and tunes the electron-nuclear dipole-dipole correlation 
time to the proton Larmor frequency; an ideal situation 
for efﬁ  cient spin-lattice (T1) relaxation. This mechanism 
is operative only from about 0.5 to 3.0 T. At these ﬁ  eld 
strengths, T1 weighted pulse sequences can be used and 
the presence of the contrast agent indicated by an increase 
in the signal intensity. Because T1 contrast agents create 
signal enhancement on T1 weighted pulse sequence, they 
are generally thought to be more desirable than T2 contrast 
agents that create signal loss. Furthermore, future clinical 
applications of these contrast agents are likely to be per-
formed at either 1.5 or 3.0 T.
In summary we have demonstrated a target-speciﬁ  c MRI 
contrast agent for tumor cells expressing high afﬁ  nity folate 
receptor. The Gd(III)-DOTA-G5-FA contrast nanoparticle 
speciﬁ  cally binds to xenograft tumors established with 
human epithelial cancer cells (KB) which over-express 
folate receptor and generates statistically signiﬁ  cant signal 
enhancement in tumors when compared to signal enhance-
ment generated by non-targeted Gd(III)-DOTA-G5 contrast 
agent. The speciﬁ  c enhancement observed in liver and 
kidney is due to presence of folate receptor in these tissues 
(Parker et al 2005). We have used 3D MR data to examine 
signals from the entire tumor or organ and the KS statistical 
test to establish differences in the histograms of targeted 
versus non-targeted contrast nanoparticles. We report a con-
trolled, statistically signiﬁ  cant and tissue speciﬁ  c increase 
in MR signal intensity in tumors for targeted dendrimer 
nanoparticles compared with the non-targeted nanoparticles. 
While we believe that based on this approach translational 
research may be possible, this clearly will require more 
complete GLP toxicity studies that are beyond the scope of 
the current work.
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